SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001640334-19-002273
Filing Date
2019-11-13
Accepted
2019-11-13 15:36:16
Documents
43
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 6-K nymx_6k.htm 6-K 7961
2 EX-99.1 nymx_ex991.htm EX-99.1 271221
3 EX-99.2 nymx_ex992.htm EX-99.2 9936
4 EX-99.3 nymx_ex993.htm EX-99.2 10303
11 nymx_ex991img1.jpg GRAPHIC 19253
  Complete submission text file 0001640334-19-002273.txt   1603399

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT nymx-20190930.xml EX-101.INS 260875
6 XBRL TAXONOMY EXTENSION SCHEMA nymx-20190930.xsd EX-101.SCH 49085
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nymx-20190930_cal.xml EX-101.CAL 26171
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nymx-20190930_def.xml EX-101.DEF 53132
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE nymx-20190930_lab.xml EX-101.LAB 141291
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nymx-20190930_pre.xml EX-101.PRE 108823
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-12033 | Film No.: 191213590
SIC: 2835 In Vitro & In Vivo Diagnostic Substances